UDP-003

Phase 1Small molecule

UDP-003 is one of 4 small molecule programs targeting Atherosclerotic Cardiovascular Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atherosclerotic Cardiovascular DiseaseRecruiting

Atherosclerotic Cardiovascular DiseasePhase 1

Recruiting

Competition

Competitive Landscape

3 competitors in Atherosclerotic Cardiovascular Disease

#DrugCompanyPhaseTrials

Leqvio

Novartis

Approved

3 2

Maridebart Cafraglutide

Amgen

Phase 3

1 3

Pelacarsen

Novartis

Phase 3

1 4

UDP-003

CCyclarity Therapeutics, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Atherosclerotic Cardiovascular Disease

NCT06813339

Clinical

Trials by Indication[1]

Atherosclerotic Cardiovascular Disease1 trial

A Double Blind, Placebo-controlled Study in Healthy Participants to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of UDP-003 and Followed by an Open-label Multiple-dose Patient Cohort

Recruiting·CCyclarity Therapeutics, Inc.·Phase 1·NCT06813339·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for UDP-003. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — UDP-003 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for UDP-003. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cyclarity Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCyclarity Therapeutics, Inc.

UDP-003

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Atherosclerotic Cardiovascular Disease1 trial

References

Drug Info

Quick Facts

Related News